Effects of luseogliflozin on the secretion of islet hormones and incretins in patients with type 2 diabetes

• Published in: Endocrine Journal Vol. 69; no. 6; pp. 681 - 687
• Main Authors: Takano, Koji, Bando, Satoru, Miyatsuka, Takeshi, Shichiri, Masayoshi, Taguchi, Tomomi, Motomiya, Tetsuya, Ichikawa, Raishi, Fujimoto, Kazumi, Taguchi, Madoka
• Format: Journal Article
• Language: English
• Published: Japan The Japan Endocrine Society 01.01.2022; Japan Science and Technology Agency
• Subjects: Beta cells; Blood glucose; Body fat; Body weight; Chromium; Diabetes; Diabetes mellitus (non-insulin dependent); Fat-free body mass; Glucagon; Glucagon-like peptide-1 (GLP-1); Glucose; Glucose tolerance; Hemoglobin; Hyperactivity; Insulin; Insulin resistance; Intolerance; Metabolism; Na+/glucose cotransporter; Secretion; Sodium-glucose cotransporter 2 (SGLT2) inhibitor; Type 2 diabetes; Glucagon-like peptide-1 (GLP-1); Type 2 diabetes; Sodium-glucose cotransporter 2 (SGLT2) inhibitor; Glucagon
• ISSN: 0918-8959; 1348-4540; 1348-4540
• DOI: 10.1507/endocrj.EJ21-0696

The insufficient activity of insulin and the hyperactivity of glucagon are responsible for glucose intolerance in patients with type 2 diabetes. Whereas sodium-glucose cotransporter-2 (SGLT2) inhibitors improve blood glucose levels in patients with type 2 diabetes, their effects on the secretion pro...